Poster presented at ASCO 2022 describing the preliminary resutls from a phase 1b/2 study of zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).
Poster presented at ASCO 2022 describing the preliminary resutls from a phase 1b/2 study of zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer.